pf-04634817
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01098877)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2ANTAGONIST
CCR2 antagonist
- C-C chemokine receptor type 5ANTAGONIST
CCR5 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1- Mol. weight
- 511.59 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095029 ↗
- ChEMBLCHEMBL3545032 ↗
Also known as
- pf-04634817
- pf-04634817
- pf-04634817
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01994291 | Phase 2 | Nov 1, 2013 | Pfizer |
| NCT01791855 | Phase 1 | May 1, 2013 | Pfizer |
| NCT01712061 | Phase 2 | Dec 1, 2012 | Pfizer |
| NCT01247883 | Phase 1 | Oct 1, 2010 | Incyte, Pfizer |
| NCT01140672 | Phase 1 | Jun 1, 2010 | Pfizer |
| NCT01098877 | Phase 1 | Apr 1, 2010 | Pfizer |
Showing 6 of 6 trials
Page 1 / 1